WASHINGTON, D.C. (May 4, 2005) -- Today, the Biotechnology Industry Organization (BIO) announced additional speakers at BIO VentureForum East 2005, scheduled May 9-11 at the Intercontinental Hotel-Buckhead in Atlanta, Georgia.
BIO VentureForum East is the largest annual East Coast regional investor conference for venture stage biotechnology and healthcare firms. It features plenary sessions and workshops on financing and partnering trends in the biotechnology industry, networking receptions, and presentations by more than 90 biotech companies which have been selected by an advisory board of leading equity capital leaders.
The plenary session from 8 – 9:45am on Wednesday, May 11th, will be a roundtable discussion on Industry Trends for In-licensing and Partnering. Pharmaceutical and biotech executives will discuss pipeline sustainability and examine the value of collaboration. Panelists will also discuss partnership strategies and consequences. Kristopher D. Ford, Corporate Strategy and Business Development for UCB Pharma Inc., will moderate. Panelists include:
· Donald L. Drakeman, President & CEO, Medarex, Inc.;
· Robert J. Gould, PhD, Vice President of Licensing and External Research, Merck Research Labs;
· John D. Mendlein, PhD, JD, Chairman & CEO, Affinium Pharmaceuticals;
· Herbert S. Ormsbee, PhD, Senior Director of Licensing & Development, Pfizer Inc.;
· John P. Richard, President, BioGrowth.
Thomas H. McLain will present the luncheon keynote address “Managing Transformative Growth” from 12 – 1:30pm on May 11th. McLain is Chairman, CEO and President of Nabi Biopharmaceuticals as well as Chairman of BioFlorida. Headquartered in Florida, Nabi Biopharmaceuticals ended 2004 with $103 million in cash assets and positive cash flow from operations.
For more information about BIO VentureForum East, please visit http://bvf-east.bio.org/ Registration is complimentary for credentialed members of the news media. Reporters and editors working full-time for print or broadcast news organizations may register onsite with valid media credentials.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in 31 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.